Drug Profile
Research programme: telomerase inhibitors - Bristol-Myers Squibb
Alternative Names: Telomerase inhibitors research programmeLatest Information Update: 12 Jul 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Bristol-Myers Squibb; Nonindustrial source
- Class
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Mar 1998 Preclinical development for Cancer in USA (Unknown route)